ArticleFrontiers in microbiology2025
Exploring drug resistance genes in
Article in Frontiers in microbiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Recent Advances and Future Perspectives in the Detection of Carbapenem-ResistantInfection and drug resistance · 2026Review
- Next-generation sequencing in the etiological diagnosis of severe childhood pneumonia.Frontiers in pediatrics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: With the rising incidence of infectious diseases, the overuse of antibiotics has become a serious problem in clinical practice. In recent years, metagenomic next-generation sequencing (mNGS) has emerged as a promising alternative, offering advantages such as rapid turnaround, broad-spectrum detection, and comprehensive coverage. However, its clinical utility for antimicrobial resistance testing remains to be fully established. Methods: In this study, we evaluated the effectiveness of mNGS in detecting antimicrobial resistance in Acinetobacter baumannii using 53 clinical samples. The performance of mNGS was compared with conventional culture-based methods. In addition, clinical judgment of drug resistance was used as a reference to assess concordance between sequencing results and patient treatment. Results: Metagenomic sequencing produced an average of 8.4 × 10⁷ reads per sample and identified 61 resistance loci-20 of which appeared in at least five isolates. Among the A. baumannii-positive samples, class-specific accuracy of mNGS exceeded 80% for β-lactams, aminoglycosides, quinolones, and minocycline, underscoring its strong performance in comprehensive resistome profiling. We further investigated resistance-associated genes in A. baumannii that appeared with high frequency, including enzymatic inactivation mechanisms (ADC-type cephalosporinases and OXA-type oxacillinases), efflux systems (AbaQ, AbeM), and RND-type efflux pumps (adeIJK/adeN and adeFGH/adeL). Discussion: Our findings demonstrate a high concordance between mNGS results, culture-based methods, and clinical evaluations, highlighting the potential of mNGS as a reliable tool for assessing antimicrobial resistance in
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.